This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by CHIHARA, K. Articles by FUJITA, T. Search for Related Content PubMed PubMed Citation Articles by CHIHARA, K. Articles by FUJITA, T.

L-Dopa Stimulates Release of Hypothalamic Growth Hormone-Releasing Hormone in Humans^*

Third Division, Department of Medicine, Kobe University School of Medicine Kobe 650, Japan

Address correspondence and requests for reprints to: Simeon I. Taylor, M.D., Ph.D., National Institutes of Health, Building 10, Room 8S-243, Bethesda, Maryland 20892.

A sensitive RIA for human GH-releasing hormone-(l–44)-NH₂ [hGHRH-(l–44)-NH₂] was developed which allows its measurement in human plasma extracts. The assay did not detect hGHRH-(l–37)-OH or hGHRH-(l–40)-OH. A method to extract hGHRH from plasma was developed using silicic acid and acid-acetone, by which recovery of synthetic hGHRH-(l–44)-NH₂ from plasma averaged 74.3%. Serial dilutions of plasma extracts gave an inhibition curve parallel with that of synthetic hGHRH-(l–44)-NH₂ in the RIA system. On Sephadex G-50 columns, hGHRH-like immunoreactivity (hGHRH-LI) in plasma extracts eluted as a single peak corresponding to hGHRH-(l–44)-NH₂. This hGHRH-LI peak, when subjected to reverse phase HPLC, emerged at the position where hGHRH-(l–44)-NH₂ was eluted. hGHRH-LI was detectable in the peripherally circulating plasma of all subjects tested. The mean basal level of plasma hGHRH-LI in normal subjects was 9.4 ± 0.7 (±SE) pg/ml (n = 22; range, 2.8–18.1 pg/ml), comparable to the basal plasma hGHRH-LI concentration in patients with hypothalamic lesions (11.3 ± 1.1 pg/ml; n = 7). Oral administration of L-dopa (0.5 g) caused a significant increase in both plasma hGHRH-LI and GH levels in normal subjects, and the plasma hGHRH-LI peak slightly preceded or coincided with that of plasma GH in individual subjects. There was also a significant correlation between plasma hGHRH-LI and the GH rises after L-dopa administration when their net increments were compared. All of the patients with hypothalamic lesions had significant increases in plasma GH after hGHRH-(l–44)- NH₂ injection (1 µg/kg BW, iv), indicating the presence of functioning somatotrophs in their pituitaries. When L-dopa was orally administered to these patients, neither plasma hGHRHLI nor GH concentration changed throughout a 120-min observation period.

These findings suggest that 1) hGHRH, immunologically and chromatographically indistinguishable from synthetic hGHRH-(l–44)-NH₂, is detectable in peripheral plasma in humans; 2) Ldopa stimulates the release of hypothalamic hGHRH, alterations of which are reflected in changes in peripheral levels; and 3) the source of circulating hGHRH is not restricted to the hypothalamus, since hGHRH-LI is present in the peripheral plasma of patients with hypothalamic lesions in amounts similar to those found in normal subjects.

^* This work was supported in part by research grantsfrom the Japanese Ministry of Health and Welfare; the Japanese Ministry of Education, Science, and Culture; and the Growth Science Foundation for 1984.

Received July 17, 1985.

This article has been cited by other articles:

				R. G. Smith, L. Betancourt, and Y. Sun Molecular Endocrinology and Physiology of the Aging Central Nervous System Endocr. Rev., April 1, 2005; 26(2): 203 - 250. [Abstract] [Full Text] [PDF]

				E. Friess, T. Kuempfel, J. Winkelmann, D. Schmid, M. Uhr, R. Rupprecht, F. Holsboer, and C. Trenkwalder Increased Growth Hormone Response to Apomorphine in Parkinson Disease Compared With Multiple System Atrophy Arch Neurol, February 1, 2001; 58(2): 241 - 246. [Abstract] [Full Text] [PDF]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]

				A. Cicognani, E. Cacciari, V. Vecchi, M. Cau, A. Balsamo, P. Pirazzoli, M. T. Tosi, P. Rosito, and G. Paolucci Differential Effects of 18- and 24-Gy Cranial Irradiation on Growth Rate and Growth Hormone Release in Children With Prolonged Survival After Acute Lymphocytic Leukemia Arch Pediatr Adolesc Med, November 1, 1988; 142(11): 1199 - 1202. [Abstract] [PDF]

				M. L. VANCE and M. O. THORNER Growth-Hormone-Releasing Hormone: A Clinical Update Ann Intern Med, September 1, 1986; 105(3): 447 - 449. [Abstract] [PDF]